SEC 13F Intelligence

Managers / Q3 2020 · view latest →

Aquilo Capital Management, LLC

CIK 0001591986 · ONE LETTERMAN DRIVE, SUITE D4900, BUILDING D, SAN FRANCISCO, CA, 94129 · 415-635-0140

Reported Value
$945M
Q3 2020
Positions
17
Filings on Record
27
2019–present window
Filed
Nov 16, 2020
original filing

Summary

Aquilo Capital Management, LLC reported $945M in U.S.-listed holdings across 17 positions for Q3 2020.

Its largest position, SPRO, represents 5.3% of the portfolio.

Compared with Q2 2020, the fund opened 4 new positions and exited 1.

Portfolio Metrics

Turnover
+10.2%
vs prior filed quarter
Top-10 Concentration
+24.0%
share of reported value
Largest Position
+5.3%
Spero Therapeutics
New / Exited
4 / 1
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q1 ’19: $226MQ1 ’19Q2 ’19: $288MQ3 ’19: $142MQ4 ’19: $266MQ1 ’20: $257MQ1 ’20Q2 ’20: $496MQ3 ’20: $945MQ4 ’20: $481MQ1 ’21: $553MQ1 ’21Q2 ’21: $385MQ3 ’21: $551MQ4 ’21: $882MQ1 ’22: $680MQ1 ’22Q2 ’22: $293MQ3 ’22: $277MQ4 ’22: $266MQ1 ’23: $241MQ1 ’23Q2 ’23: $180MQ3 ’23: $110MQ4 ’23: $160MQ1 ’24: $133MQ1 ’24Q2 ’24: $104MQ3 ’24: $132MQ4 ’24: $66MQ1 ’25: $56MQ1 ’25Q2 ’25: $0Q3 ’25: $0filingsflow.com

Portfolio Composition

By security type
ETP: 74.1%Common Stock: 22.9%Other: 2.1%ADR: 0.9%
  • ETP · 74.1% · $700M
  • Common Stock · 22.9% · $216M
  • Other · 2.1% · $20M
  • ADR · 0.9% · $8M

Quarter-over-Quarter Changes full breakdown →

vs Q2 2020 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
IWMISHARES TR RUSSELL 2000NEW+1.70M1.70M+$255M$255M
MAGENTA THERAPEUTICS INCNEW+958.6K958.6K+$7M$7M
AC IMMUNE SANEW+463.6K463.6K+$2M$2M
GMABGENMAB A/SNEW+50.0K50.0K+$2M$2M
SPROSPERO THERAPEUTICS INCADDED+2.55M4.50M+$24M$50M
XBISPDR SER TR S&P BIOTECHADDED+2.00M4.00M+$222M$446M
MORPHOSYS AGSOLD OUT−95.9K0−$3M$0
ARGXARGENX SETRIMMED−28.3K7.5K−$6M$2M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q3 2020

15 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1SPROSPERO THERAPEUTICS INChistory →COM5.31%$50M4.50M
2BLUEPRINT MEDICINES CORPCOM3.79%$36M385.7K
3DICERNA PHARMACEUTICALS INCCOM2.62%$25M1.37M
4QUREUNIQURE NVhistory →SHS2.46%$23M631.1K
5ARWRARROWHEAD PHARMACEUTICALS INhistory →COM2.39%$23M523.4K
6ANABANAPTYSBIO INChistory →COM2.31%$22M1.48M
7NGM BIOPHARMACEUTICALS INCCOM1.72%$16M1.02M
8RGNXREGENXBIO INChistory →COM1.49%$14M510.8K
9PROQR THRAPEUTICS N VSHS EURO1.16%$11M2.28M
10PIERIS PHARMACEUTICALS INCCOM0.81%$8M3.68M
11MAGENTA THERAPEUTICS INCCOM0.69%$7M958.6K
12GALAPAGOS NVSPON ADR0.49%$5M32.5K
13AC IMMUNE SASHS0.24%$2M463.6K
14ARGXARGENX SESPONSORED ADR0.21%$2M7.5K
15GMABGENMAB A/SSPONSORED ADS0.19%$2M50.0K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q3 2025$01Nov 12, 202513F-HRchanges · EDGAR ↗
Q2 2025$01Aug 6, 202513F-HRchanges · EDGAR ↗
Q1 2025$56M13May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$66M15Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$132M14Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$104M13Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$133M10May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$160M10Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$110M12Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$180M13Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$241M12May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$266M13Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$277M15Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$293M13Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$680M14May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$882M14Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$551M14Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$385M15Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$553M17May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$481M17Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$945M17Nov 16, 202013F-HRchanges · EDGAR ↗
Q2 2020$496M14Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$257M14May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$266M12Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$142M11Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019$288M13Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$226M14May 15, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.